Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

862 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort Study.
Shimose S, Kawaguchi T, Iwamoto H, Tanaka M, Miyazaki K, Ono M, Niizeki T, Shirono T, Okamura S, Nakano M, Suga H, Yamaguchi T, Yokokura Y, Noguchi K, Koga H, Torimura T. Shimose S, et al. Among authors: okamura s. Nutrients. 2020 Apr 13;12(4):1076. doi: 10.3390/nu12041076. Nutrients. 2020. PMID: 32295043 Free PMC article.
Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study.
Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Tajiri N, Satani M, Niizeki T, Aino H, Okamura S, Iwamoto H, Shimose S, Shirono T, Koga H, Torimura T; Kurume Liver Cancer Study Group of Japan. Nakano M, et al. Among authors: okamura s. Cancer Med. 2015 Dec;4(12):1836-43. doi: 10.1002/cam4.548. Epub 2015 Oct 16. Cancer Med. 2015. PMID: 26471348 Free PMC article.
Alternative treatments in advanced hepatocellular carcinoma patients with progressive disease after sorafenib treatment: a prospective multicenter cohort study.
Nakano M, Tanaka M, Kuromatsu R, Nagamatsu H, Satani M, Niizeki T, Okamura S, Iwamoto H, Shimose S, Shirono T, Noda Y, Koga H, Torimura T; Kurume Liver Cancer Study Group Of Japan. Nakano M, et al. Among authors: okamura s. Oncotarget. 2016 Sep 27;7(39):64400-64409. doi: 10.18632/oncotarget.10794. Oncotarget. 2016. PMID: 27462865 Free PMC article.
Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability toward Adverse Events.
Iwamoto H, Suzuki H, Shimose S, Niizeki T, Nakano M, Shirono T, Okamura S, Noda Y, Kamachi N, Nakamura T, Masuda A, Sakaue T, Tanaka T, Nakano D, Sakai M, Yamaguchi T, Kuromatsu R, Koga H, Torimura T. Iwamoto H, et al. Among authors: okamura s. Cancers (Basel). 2020 Apr 19;12(4):1010. doi: 10.3390/cancers12041010. Cancers (Basel). 2020. PMID: 32325921 Free PMC article.
Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study.
Shimose S, Iwamoto H, Niizeki T, Shirono T, Noda Y, Kamachi N, Okamura S, Nakano M, Suga H, Kuromatsu R, Yamaguchi T, Kawaguchi T, Tanaka M, Noguchi K, Koga H, Torimura T. Shimose S, et al. Among authors: okamura s. Cancers (Basel). 2020 Jul 11;12(7):1867. doi: 10.3390/cancers12071867. Cancers (Basel). 2020. PMID: 32664489 Free PMC article.
Alternating Lenvatinib and Trans-Arterial Therapy Prolongs Overall Survival in Patients with Inter-Mediate Stage HepatoCellular Carcinoma: A Propensity Score Matching Study.
Shimose S, Iwamoto H, Tanaka M, Niizeki T, Shirono T, Noda Y, Kamachi N, Okamura S, Nakano M, Suga H, Yamaguchi T, Kawaguchi T, Kuromatsu R, Noguchi K, Koga H, Torimura T. Shimose S, et al. Among authors: okamura s. Cancers (Basel). 2021 Jan 5;13(1):160. doi: 10.3390/cancers13010160. Cancers (Basel). 2021. PMID: 33466496 Free PMC article.
Evaluating the therapeutic effect of lenvatinib against advanced hepatocellular carcinoma by measuring blood flow changes using contrast-enhanced ultrasound.
Kamachi N, Nakano M, Okamura S, Niizeki T, Iwamoto H, Shimose S, Shirono T, Noda Y, Kuromatsu R, Koga H, Torimura T. Kamachi N, et al. Among authors: okamura s. Cancer Rep (Hoboken). 2022 Feb;5(2):e1471. doi: 10.1002/cnr2.1471. Epub 2021 Jun 9. Cancer Rep (Hoboken). 2022. PMID: 34105904 Free PMC article.
First-line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study.
Shimose S, Hiraoka A, Nakano M, Iwamoto H, Tanaka M, Tanaka T, Noguchi K, Aino H, Ogata K, Kajiwara M, Itano S, Yokokura Y, Yamaguchi T, Kawano H, Matsukuma N, Suga H, Niizeki T, Shirono T, Noda Y, Kamachi N, Okamura S, Kawaguchi T, Koga H, Torimura T. Shimose S, et al. Among authors: okamura s. Cancer Med. 2021 Dec;10(23):8530-8541. doi: 10.1002/cam4.4367. Epub 2021 Oct 24. Cancer Med. 2021. PMID: 34693661 Free PMC article.
Durable complete response is achieved by balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma.
Shirono T, Iwamoto H, Niizeki T, Shimose S, Kajiwara A, Suzuki H, Kamachi N, Noda Y, Okamura S, Nakano M, Kuromatsu R, Murotani K, Koga H, Torimura T. Shirono T, et al. Among authors: okamura s. Hepatol Commun. 2022 Sep;6(9):2594-2604. doi: 10.1002/hep4.2016. Epub 2022 Jun 3. Hepatol Commun. 2022. PMID: 35656864 Free PMC article.
862 results